The content on this site is intended for healthcare professionals only
ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in t...
Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA
11 Jun 2021
CLL14: Venetoclax plus obinutuzumab in untreated CLL
Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany
11 Jun 2021
CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax fo...
Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, N...
10 Jun 2021
Can multiple endpoints in MM clinical papers create new insights?
Prof Evangelos Terpos and Prof Nina Shah
9 Jun 2021
Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in ...
Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US
16 Apr 2021
Reduced intensity allogeneic HSCT to hypomethylating therapy or best supportive ...
Dr Ryotaro Nakamura - City of Hope, California, USA
17 Feb 2021
OncoAlert and ecancer weekly roundup for February 01 - 06, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
9 Feb 2021
Emerging treatments for relapsed/refractory Hodgkin’s lymphoma in China
Dr Qingqing Cai - Sun Yat-Sen University, Guangzhou, China
29 Jan 2021
OncoAlert and ecancer weekly roundup for January 11 - 17, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
21 Jan 2021
Haematology updates from SIOG 2020
Dr Tanya Wildes - SIOG Science & Education Committee Chair
13 Jan 2021
The Burkitt lymphoma international prognostic index
Prof Adam Olszewski - Brown University, Providence, USA
24 Dec 2020
OncoAlert Colloquium Day 4: Gynae-oncology, lymphoma, sarcoma and melanoma
Dr Dizon, Dr Trent, Dr Cordoba, Dr Rolfo, Dr Haanen
23 Dec 2020
